{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Response rates were classified according to the International Uniform Response Criteria for Multiple Myeloma (Durie et al, 2006).","groups":[{"description":"Intravenous (IV) infusions of natalizumab 300 mg once every 28 days for 6 months.","id":"OG000","title":"Natalizumab 300 mg"},{"description":"Intravenous (IV) infusions of natalizumab 450 mg once every 28 days for 6 months.","id":"OG001","title":"Natalizumab 450 mg"}],"populationDescription":"ORR was not calculated because the study was terminated early.","reportingStatus":"POSTED","timeFrame":"Day 1 up to Month 6","title":"Objective Response Rate (ORR)","type":"PRIMARY"}